Enveric Biosciences
Enveric Biosciences is a biotechnology company focused on developing innovative therapeutics aimed at improving the quality of life for patients affected by the side effects of cancer treatments and mental health disorders. The company is exploring natural compounds, particularly cannabinoids, to create new prescription medications that address unmet medical needs. Enveric's lead program, EB-003, targets difficult mental health issues such as depression, anxiety, and addiction, promoting neuroplasticity without causing hallucinations. Additionally, the company is advancing EB-002, a synthetic prodrug of psilocin, as a potential treatment for psychiatric disorders. Through its research, Enveric Biosciences aims to provide effective solutions for patients facing challenging health conditions.
1 past transactions
MagicMed Industries
Acquisition in 2021
MagicMed Industries Inc. is a biotechnology company based in Calgary, Canada, focused on developing psychedelic-derived medicinal and consumer products. Established in 2020, the company is creating a library of novel derivative molecules, primarily targeting psilocybin, but also including other compounds like N,N-dimethyltryptamine (DMT). MagicMed's aim is to develop patented products that are more effective and safer for various psychological conditions. The company’s Psybrary serves as a molecular derivatives library, facilitating the innovation of psychedelic-derived pharmaceuticals, nutraceuticals, and consumer goods. This approach allows researchers to leverage unique processes and expertise that may not be available within traditional pharmaceutical and consumer goods companies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.